UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity

The Journal of immunology (1950), 2014-10, Vol.193 (8), p.3835-3841

2014

Volltextzugriff (PDF)

Tumor Plasticity and Resistance to Immunotherapy

Trends in Cancer, 2020-05, Vol.6 (5), p.432-441

2020

Volltextzugriff (PDF)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication

The Journal of clinical investigation, 2022-04, Vol.132 (8)

2022

Volltextzugriff (PDF)

HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (20), p.5723-5733

2014

Volltextzugriff (PDF)

Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy

Frontiers in oncology, 2019-04, Vol.9, p.215-215

2019

Volltextzugriff (PDF)

Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

Pharmacology & therapeutics (Oxford), 2021-03, Vol.219, p.107692-107692, Article 107692

2021

Volltextzugriff (PDF)

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer

Cancer research (Chicago, Ill.), 2016-01, Vol.76 (2), p.283-292

2016

Volltextzugriff (PDF)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

Journal for immunotherapy of cancer, 2020-03, Vol.8 (1), p.e000326

2020

Volltextzugriff (PDF)

Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes

Cancer immunology research, 2018-01, Vol.6 (1), p.59-68

2018

Volltextzugriff (PDF)

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy

Cancers, 2021-02, Vol.13 (5), p.968

2021

Volltextzugriff (PDF)

The Use of a Humanized NSG-β2m -/- Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa

Frontiers in oncology, 2020-04, Vol.10, p.549-549

2020

Volltextzugriff (PDF)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis

Journal for immunotherapy of cancer, 2023-09, Vol.11 (9), p.e007386

2023

Volltextzugriff (PDF)

Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy

Cancers, 2021-08, Vol.13 (16), p.3942

2021

Volltextzugriff (PDF)

Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

Clinical cancer research, 2020-03, Vol.26 (6), p.1420-1431

2020

Volltextzugriff (PDF)

Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment

Cancer Immunology, Immunotherapy, 2020-02, Vol.69 (2), p.215-221

2020

Volltextzugriff (PDF)

High‐mobility group box protein 1 promotes the survival of myeloid‐derived suppressor cells by inducing autophagy

Journal of leukocyte biology, 2016-09, Vol.100 (3), p.463-470

2016

Volltextzugriff (PDF)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.350-368

2023

Volltextzugriff (PDF)

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy

JCI insight, 2019-04, Vol.4 (7)

2019

Volltextzugriff (PDF)

Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells

Cancer Immunology, Immunotherapy, 2015-10, Vol.64 (10), p.1287-1293

2015

Volltextzugriff (PDF)

CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1 + tumor cells, and extends the survival of tumor-bearing humanized mice

Oncotarget, 2017-08, Vol.8 (35), p.57964-57980

2017

Volltextzugriff (PDF)

A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation

Cancer immunology research, 2014-07, Vol.2 (7), p.610-615

2014

Volltextzugriff (PDF)

358 Characterization of the anti-tumor activity of memory cytokine enriched NK cells against tumors with neuroendocrine features

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A407-A407

2023

Volltextzugriff (PDF)

804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A902-A902

2023

Volltextzugriff (PDF)

1136 Vaccine targeting of the tumor-associated antigen brachyury reduces development of colitis-induced colorectal lesions in the APCMin/+ mouse model

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1250-A1250

2023

Volltextzugriff (PDF)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-[beta] signaling enables PD-L1-mediated tumor eradication

The Journal of clinical investigation, 2022-04, Vol.132 (8)

2022

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(140)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity

Tumor Plasticity and Resistance to Immunotherapy

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication

HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells

Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy

Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy

The Use of a Humanized NSG-β2m -/- Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis

Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy

Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment

High‐mobility group box protein 1 promotes the survival of myeloid‐derived suppressor cells by inducing autophagy

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy

Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells

CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1 + tumor cells, and extends the survival of tumor-bearing humanized mice

A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation

358 Characterization of the anti-tumor activity of memory cytokine enriched NK cells against tumors with neuroendocrine features

804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models

1136 Vaccine targeting of the tumor-associated antigen brachyury reduces development of colitis-induced colorectal lesions in the APCMin/+ mouse model

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-[beta] signaling enables PD-L1-mediated tumor eradication

Suchergebnisse filtern